Summit shares tumble on mixed data for lung cancer drug

The study results, reported on Sunday, showed that the drug, ivonescimab, had stronger benefit in patients with non-small cell lung cancer (NSCLC) in China, compared to patients in North America and Europe. Last year, Summit shares hit a record high after the company and its partner Akeso reported results from a trial conducted in China, which showed patients who took ivonescimab had better survival rates than those on Merck's blockbuster Keytruda.